LINK ALTERNATIF MBL77 OPTIONS

Not all people with CLL demand therapy. Despite all the latest advances, the iwCLL nonetheless recommends watchful observation for individuals with asymptomatic illness.86 This advice is predicated on at the very least two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).